Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]
Biomea Fusion, Inc. (BMEA)
Company Research
Source: Yahoo! Finance
After just a 4-week treatment period in type 2 diabetes patients, who had previously failed standard of care (HbA1c 7.0% and Enrollment underway in COVALENT-111 expansion cohort (n=216) to evaluate dosing duration up to 12 weeks; initial readout after 26 weeks of follow up expected in 2024. In 2023, initiated a Phase 2 study of BMF-219 in type 1 diabetes patients (COVALENT-112); initial readout anticipated in 2024. Biomea aims to deliver short-term, non-chronic treatment that will reconstitute insulin-producing beta cells, allowing diabetes patients' own bodies to durably normalize blood sugar levels. Data readouts of COVALENT-111 and COVALENT-112 in 2024 will inform the design of potentially pivotal Phase 3 studies in type 2 and type 1 diabetes, targeting 2025 initiation. In 2023, reported initial topline data from Phase 1 study of BMF-219 in acute myeloid leukemia (AML); continuing to progress COVALENT-101 in liquid tumors, COVALENT-102 in solid tumors and COVALENT-103
Show less
Read more
Impact Snapshot
Event Time:
BMEA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMEA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMEA alerts
High impacting Biomea Fusion, Inc. news events
Weekly update
A roundup of the hottest topics
BMEA
News
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Biomea Fusion, Inc. (NASDAQ: BMEA) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $15.00. They now have a "neutral" rating on the stock.MarketBeat
- Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]Yahoo! Finance
- Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswire
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
BMEA
Earnings
- 5/2/24 - Miss
BMEA
Sec Filings
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- 4/26/24 - Form ARS
- BMEA's page on the SEC website